Clearside Biomedical Inc (NASDAQ:CLSD) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 847,794 shares, a drop of 44.7% from the January 12th total of 1,532,586 shares. Approximately 4.7% of the shares of the stock are sold short. Based on an average daily volume of 148,914 shares, the short-interest ratio is currently 5.7 days.
A number of equities research analysts have weighed in on CLSD shares. Zacks Investment Research upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. Cowen restated a “buy” rating on shares of Clearside Biomedical in a research report on Wednesday, October 25th. ValuEngine downgraded Clearside Biomedical from a “sell” rating to a “strong sell” rating in a research report on Monday, February 5th. Finally, Wedbush restated a “buy” rating on shares of Clearside Biomedical in a research report on Wednesday, February 7th. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $18.33.
In other Clearside Biomedical news, Director Clay Thorp sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $7.02, for a total transaction of $105,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold 70,000 shares of company stock worth $476,500 in the last 90 days. Company insiders own 20.90% of the company’s stock.
Shares of Clearside Biomedical (CLSD) opened at $5.77 on Monday. Clearside Biomedical has a 12-month low of $5.30 and a 12-month high of $10.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.57 and a current ratio of 4.57. The firm has a market capitalization of $146.23 and a PE ratio of -3.01.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/12/clearside-biomedical-inc-clsd-short-interest-down-44-7-in-january.html.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.